SAN CLEMENTE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that management will participate in the following investor conferences: Stifel 2025 Healthcare ConferencePresentation Format: Corporate overviewPresentation Date: Wednesday, November 12, 2025Presentation Time: 10:40 a.m. ETWebcast: Click Here Jefferies London Healthcare Conference Presentation Format: Corporate o ...

SAN CLEMENTE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Jefferies Virtual Private MedTech Summit on October 1st, 2025. About Sofwave MedicalSofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using its prop ...

Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology, is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin), to improve the appearance of skin laxity on the upper arms, as well as the short-term improvement in the appearance of cellulite and treatment of acne scars. The company's Pure I ...

Core Insights - Sofwave Medical Ltd reported record quarterly revenue of $21 million in Q2 2025, reflecting a 43% year-over-year growth, and expects to achieve operating break-even for the full year [3][4][5] - The company has a strong recurring revenue stream, with $9.2 million in Q2, representing a 53% year-over-year increase, and over 40% of total revenue coming from recurring sources [4][5][9] - Sofwave's innovative technology and FDA clearances are driving rapid adoption in the aesthetic medical device market, with over 600,000 treatments conducted since launch [3][8][9] Financial Highlights - Q2 2025 revenue reached $21 million, a 43% increase from $14.6 million in Q2 2024; gross profit was $15.9 million, up 42% year-over-year [4][5][7] - First half revenue totaled $37.7 million, a 35% increase year-over-year, with gross profit of $28.6 million, reflecting a 36% growth [5][7] - The company generated $3.6 million in cash during Q2 2025, with cash and cash equivalents amounting to $24 million as of June 30, 2025 [4][5] Operational Highlights - Sofwave's technology, SUPERB™, is FDA-cleared for various aesthetic treatments, including wrinkle reduction and muscle toning, enhancing its market position [8][9] - The company has seen significant growth in brand awareness, surpassing 1 million social media followers, which supports its market presence [3][4] - Sofwave's operational discipline and strong balance sheet are key factors in its ongoing growth strategy [3][9]

Group 1 - Sofwave Medical Ltd is an emerging leader in energy-based non-invasive aesthetic medical devices [1][2] - The company will present a corporate overview and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference from June 3-5, 2025 [1][2] - Assaf Korner, the Chief Financial Officer, will be representing the company at the conference [1] Group 2 - Sofwave Medical has developed proprietary technology called SUPERB™, which is FDA-cleared for improving facial lines, wrinkles, and skin laxity [2] - The company's Pure Impact™ module utilizes 4th generation EMS technology for muscle toning and is also FDA-cleared [2] - Sofwave's products are designed to provide effective and safe aesthetic solutions for physicians and their patients [2]

Core Insights - Sofwave Medical Ltd reported a first quarter revenue of $16.7 million, reflecting a 26% year-over-year growth, with a gross margin of 76.3% [1][8] - The company achieved a recurring revenue of $7 million, marking a 49% year-over-year increase, which now constitutes over 40% of total revenue [1][5] - Sofwave's operating loss was reported at $1 million under IFRS and $0.2 million under non-IFRS, indicating stable performance compared to the previous year [1][8] Financial Highlights - First quarter revenue reached $16.7 million, a 26% increase from $13.2 million in Q1 2024 [10] - Gross profit for the quarter was $12.7 million, up 28% year-over-year [8][10] - The company maintained a gross margin of 76.3%, slightly up from 75.2% in the same quarter last year [10] - Cash and cash equivalents stood at $20.4 million as of March 31, 2025, with cash used in the quarter amounting to $1.2 million [8] Management Commentary - CEO Louis Scafuri highlighted strong revenue growth and market leadership, attributing success to new system placements and increased procedure volumes [3] - The company achieved regulatory clearance in Japan, opening new opportunities in the APAC region [4] - The launch of the LiftHD™ body applicator generated significant market enthusiasm, reinforcing Sofwave's position in non-invasive regenerative aesthetics [4][5] Operational Highlights - Over 520,000 treatments have been conducted since the initial market approval of Sofwave's technology [9] - The company is on track to achieve operating break-even in 2025 [9] - The widespread use of GLP-1 inhibitors is driving demand for Sofwave's skin lifting and muscle toning treatments [5]